PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33823014-0 2021 Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Temozolomide 0-12 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 139-142 35452002-0 2022 PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. Temozolomide 103-115 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 164-167 34067729-0 2021 From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Temozolomide 44-56 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 64-67 34067729-1 2021 In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. Temozolomide 59-71 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 98-101 34067729-1 2021 In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. Temozolomide 73-76 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 98-101 34067729-2 2021 We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Temozolomide 43-46 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 183-186 34830935-0 2021 A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide. Temozolomide 171-183 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 59-83 34934580-3 2021 In this case report, a 28-year-old male presents with a WHO grade 4 isocitrate dehydrogenase (IDH)-mutant astrocytoma (formerly secondary glioblastoma) of the left occipital/parietal lobe after receiving 45 Gy and two cycles of adjuvant temozolomide four years prior for a grade 3 IDH-mutant astrocytoma. Temozolomide 237-249 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 94-97 34934580-3 2021 In this case report, a 28-year-old male presents with a WHO grade 4 isocitrate dehydrogenase (IDH)-mutant astrocytoma (formerly secondary glioblastoma) of the left occipital/parietal lobe after receiving 45 Gy and two cycles of adjuvant temozolomide four years prior for a grade 3 IDH-mutant astrocytoma. Temozolomide 237-249 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 281-284 34335021-16 2021 Moreover, IDH1mutant glioblastomas with WT1 overexpression are associated with late RFI particularly if temozolomide with additional chemotherapies are used. Temozolomide 104-116 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 10-14 35452002-2 2022 PATIENTS AND METHODS: Among 30 patients showing residual lesions of IDH-mutant lower-grade glioma, we compared the tumor-to-normal brain tissue ratio of standardized uptake values (SUVT/N) from 11C-met PET at the time of discontinuing TMZ-adjuvant chemotherapy with putative predictive factors including age, Karnofsky Performance Scale, number of courses of adjuvant therapy, residual tumor size, and promotor methylation status of O6-methylguanine-DNA methyl-transferase gene (MGMT). Temozolomide 235-238 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 68-71 35351796-6 2022 In women with IDH-wildtype high-grade astrocytomas there was a negative correlation of severe cytopenia in general and thrombocytopenia in specific during temozolomide RCT with OS independent from other predictors (92 (77-111) vs. 73 (21-127) weeks, p-values <0.05). Temozolomide 155-167 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 14-17 33432322-3 2021 In the first case, the primary tumor harbored an IDH1 mutation with chromosome 1p/19q partial deletions, which covered 19q13 and exhibited a durable initial response to radiotherapy and temozolomide (TMZ) treatment. Temozolomide 186-198 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 49-53 35173295-0 2022 Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. Temozolomide 16-19 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 95-99 34969742-1 2022 BACKGROUND: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Temozolomide 129-141 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 204-228 34969742-1 2022 BACKGROUND: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Temozolomide 129-141 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 230-233 33475680-0 2021 The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic. Temozolomide 12-24 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 68-71 33524191-1 2021 BACKGROUND: IDH-mutant anaplastic astrocytomas (AA) are chemosensitive tumours for which the best choice of adjuvant chemotherapy between procarbazine, CCNU and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear. Temozolomide 182-194 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 12-15 33524191-1 2021 BACKGROUND: IDH-mutant anaplastic astrocytomas (AA) are chemosensitive tumours for which the best choice of adjuvant chemotherapy between procarbazine, CCNU and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear. Temozolomide 196-199 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 12-15 33524191-7 2021 CONCLUSIONS: RT + PCV significantly improved PFS compared to RT + TMZ for IDH-mutant AA. Temozolomide 66-69 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 74-77 33524191-10 2021 Our study in a national cohort of IDH-mutant AA defined according the 2016 WHO classification shows for the first time that the RT + PCV regimen significantly improves PFS in comparison to the RT + TMZ regimen. Temozolomide 198-201 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 34-37 33914057-12 2021 A predictive prognostic Cox proportional hazards model identified that independent prognostic factors for IDH1/2mt anaplastic astrocytoma patients included; age, mini-mental state examination score, treatment with concurrent and/or adjuvant temozolomide, the epigenetic classifiers, PDGFRA amplification, CDKN2A/B homozygous deletion, PI3K mutations and total CNV load. Temozolomide 241-253 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 106-112 35351965-11 2022 Although temozolomide attenuated invasion of glioblastoma cells with mutant IDH1 more than those with wild-type IDH1, the combination of RSL3 and temozolomide similarly impaired invasive ability of glioblastoma cells in spite of IDH1 status. Temozolomide 9-21 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 76-80 33296093-3 2021 Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas. Temozolomide 15-18 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 91-115 33296093-3 2021 Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas. Temozolomide 15-18 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 117-120 33296093-3 2021 Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas. Temozolomide 15-18 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 214-217 33296093-3 2021 Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas. Temozolomide 63-66 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 91-115 33296093-3 2021 Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas. Temozolomide 63-66 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 117-120 33628600-0 2021 Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Temozolomide 65-68 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 77-80 33628600-1 2021 Objective: O6methylguanine-DNA methyltransferase (MGMT) promoter methylation is a biomarker widely used to predict the sensitivity of IDH-wildtype glioblastoma to temozolomide therapy. Temozolomide 163-175 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 134-137 33628600-6 2021 We demonstrated that MGMT promoter methylation status, as determined by a high cutoff value (>=30%) in pyrosequencing, could be used to significantly stratify the survival of 50 IDH-mutant glioblastomas receiving temozolomide therapy (cohort A); this result was validated in another cohort of 25 IDH-mutant glioblastomas (cohort B). Temozolomide 213-225 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 178-181 33432322-3 2021 In the first case, the primary tumor harbored an IDH1 mutation with chromosome 1p/19q partial deletions, which covered 19q13 and exhibited a durable initial response to radiotherapy and temozolomide (TMZ) treatment. Temozolomide 200-203 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 49-53 32166314-1 2020 BACKGROUND: Emerging data suggest that a subset of patients with diffuse IDH-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors. Temozolomide 128-140 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 73-76 33255358-9 2020 In other words, IDH1-mutated GBMSC showed greater sensitivity to the coadministration of temozolomide and meclizine. Temozolomide 89-101 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 16-20 33400009-0 2021 Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. Temozolomide 108-120 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 67-71 32958546-0 2020 Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Temozolomide 81-93 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 50-54 32958546-2 2020 IDH1-mutant patients are increasingly being treated with temozolomide, but early detection of response remains a challenge and there is a need for complementary imaging methods to assess response to therapy prior to tumor shrinkage. Temozolomide 57-69 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 32958546-3 2020 The goal of this study was to determine the value of magnetic resonance spectroscopy (MRS)-based metabolic changes for detection of response to temozolomide in both genetically engineered and patient-derived mutant IDH1 models. Temozolomide 144-156 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 215-219 32958546-9 2020 SIGNIFICANCE: These findings show that glutamate can be used as a noninvasive, imageable metabolic marker for early assessment of tumor response to temozolomide, with the potential to improve treatment strategies for mutant IDH1 patients. Temozolomide 148-160 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 224-228 32166314-1 2020 BACKGROUND: Emerging data suggest that a subset of patients with diffuse IDH-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors. Temozolomide 142-145 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 73-76 31443404-7 2019 In vitro and in vivo studies were conducted for further investigations to verify these results, and the addition of Bev to TMZ showed a significant antitumor effect only in the IDH1-mutant GBM xenograft model. Temozolomide 123-126 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 177-181 32942564-1 2020 Approximately 96% of patients with glioblastomas (GBM) have IDH1 wildtype GBMs, characterized by extremely poor prognosis, partly due to resistance to standard temozolomide treatment. Temozolomide 160-172 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 60-64 30536544-6 2019 TMZ-naive hypermutated tumors were marked by absence of IDH1 somatic mutation and MGMT promoter (pMGMT) methylation, two genomic traits that were significantly associated with the TMZ-induced hypermutagenic event in glioblastoma, and harbored inherited alterations in the mismatch repair (MMR) machinery. Temozolomide 0-3 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 56-60 29848907-0 2018 MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. Temozolomide 118-130 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 146-149 30863099-5 2019 Herein, a 66-year-old man with brainstem anaplastic astrocytoma isocitrate dehydrogenase (IDH) wild type was treated initially with combined radiotherapy, temozolomide, and apatinib. Temozolomide 155-167 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 90-93 30771200-13 2019 CONCLUSIONS: Addition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population. Temozolomide 35-38 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 57-60 30771200-13 2019 CONCLUSIONS: Addition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population. Temozolomide 43-46 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 57-60 30446361-0 2019 Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. Temozolomide 87-99 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 103-106 29625108-3 2018 The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1alpha expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment. Temozolomide 318-330 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 62-66 29679127-10 2018 In IDH wild-type astrocytic tumors, hypermethylation of the promoter of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) gene is predictive for benefit from the alkylating agent temozolomide. Temozolomide 198-210 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 3-6 28427200-1 2017 PURPOSE: Numerous studies have reported that glioma patients with isocitrate dehydrogenase 1(IDH1) R132H mutation are sensitive to temozolomide treatment. Temozolomide 131-143 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 93-97 29393185-6 2018 At present, MGMT promoter methylation is considered as a predictive marker for response of glioblastoma to chemotherapy with temozolomide, particularly in elderly patients, 1p/19q co-deletion is a molecular signature of oligodendroglial tumors and predictive marker for response of anaplastic gliomas to PCV chemotherapy, and IDH1/IDH2 mutations have a strong favorable prognostic value across all glioma histopathological grades. Temozolomide 125-137 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 326-330 28625978-3 2017 We therefore hypothesized that a strategy combining NAD+ biosynthesis inhibitors with the alkylating chemotherapeutic agent temozolomide could potentiate NAD+ depletion-mediated cytotoxicity in mutant IDH1 cancer cells. Temozolomide 124-136 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 201-205 28625978-7 2017 This effect was selective for IDH1-mutant cells and independent of methylguanine methyltransferase or mismatch repair status, which are known rate-limiting mediators of adjuvant temozolomide genotoxic sensitivity. Temozolomide 178-190 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 30-34 28625978-8 2017 Combined temozolomide and NAMPT inhibition in an in vivo IDH1-mutant cancer model exhibited enhanced efficacy compared with each agent alone. Temozolomide 9-21 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 57-61 28571041-8 2017 RESULTS: Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide. Temozolomide 233-245 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 88-92 28887717-0 2018 Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. Temozolomide 25-37 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 75-78 28887717-11 2018 Blood cell counts during the concomitant TMZ phase can help predict OS in patients with GBM, IDH-wildtype receiving the standard treatment protocol. Temozolomide 41-44 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 93-96 28427200-8 2017 RESULTS: The IDH1 R132H overexpressing cells were more sensitive to temozolomide than WT and the control, and Nrf2 was significantly decreased in IDH1 R132H overexpressing cells. Temozolomide 68-80 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 13-17 28427200-10 2017 The nuclear translocation of Nrf2 in IDH1 R132H overexpressing cells was lower than the WT and the control groups after temozolomide treatment. Temozolomide 120-132 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 37-41 28427200-11 2017 When compared with WT cells, NQO1 expression was reduced in IDH1 R132H cells, especially after temozolomide treatment. Temozolomide 95-107 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 60-64 26936071-3 2016 RESULTS: We identified a single significant correlation resulting in increased overall survival from temozolomide in lower-grade glioma with IDH1 R132H mutations. Temozolomide 101-113 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 141-145 28202508-6 2017 Targeting the PARP DNA repair pathway extensively sensitized IDH1-mutated glioma cells to TMZ. Temozolomide 90-93 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 61-65 27764705-0 2016 IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Temozolomide 187-199 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-3 27764705-1 2016 PURPOSE: This study aimed to investigate the potential association between IDH mutation and O6-methyl-guanine methyl transferase (MGMT) gene promoter methylation and pseudoprogression disease (psPD) in glioblastoma multiforme (GBM) patients after concurrent temozolomide (TMZ)-based chemoradiotherapy. Temozolomide 258-270 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 75-78 27764705-1 2016 PURPOSE: This study aimed to investigate the potential association between IDH mutation and O6-methyl-guanine methyl transferase (MGMT) gene promoter methylation and pseudoprogression disease (psPD) in glioblastoma multiforme (GBM) patients after concurrent temozolomide (TMZ)-based chemoradiotherapy. Temozolomide 272-275 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 75-78 27764705-10 2016 CONCLUSION: MGMT promoter methylation and IDH1 mutation were associated with PsPD and predicted a longer median survival in GBM patients after TMZ-based chemoradiotherapy. Temozolomide 143-146 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 42-46 26936071-6 2016 CONCLUSION: Our results suggest infrequent instances of exceptional responses ascribable to tumor genomics yet corroborate the existence of an interaction of temozolomide with IDH1 mutations in lower-grade glioma. Temozolomide 158-170 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 176-180 25035396-0 2014 Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Temozolomide 97-109 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 7-11 26911558-5 2016 CASE PRESENTATION: We describe a patient who underwent surgical resection, followed by adjuvant radiation and temozolomide of a World Health Organization (WHO) III anaplastic astrocytoma in the right temporal lobe, exhibiting an IDH1 (R132H) mutation. Temozolomide 110-122 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 229-233 26373279-5 2015 In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen. Temozolomide 119-131 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 50-54 26373279-5 2015 In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen. Temozolomide 173-176 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 50-54 25283382-6 2015 Compared with control cells and cells overexpressing IDH wild type (IDH1-WT), both types of IDH1-R132H cells were more sensitive to temozolomide (TMZ) and cis-diamminedichloroplatinum (CDDP) in a time- and dose-dependent manner. Temozolomide 132-144 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 53-56 25283382-6 2015 Compared with control cells and cells overexpressing IDH wild type (IDH1-WT), both types of IDH1-R132H cells were more sensitive to temozolomide (TMZ) and cis-diamminedichloroplatinum (CDDP) in a time- and dose-dependent manner. Temozolomide 132-144 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 68-72 25283382-6 2015 Compared with control cells and cells overexpressing IDH wild type (IDH1-WT), both types of IDH1-R132H cells were more sensitive to temozolomide (TMZ) and cis-diamminedichloroplatinum (CDDP) in a time- and dose-dependent manner. Temozolomide 132-144 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 92-96 25283382-6 2015 Compared with control cells and cells overexpressing IDH wild type (IDH1-WT), both types of IDH1-R132H cells were more sensitive to temozolomide (TMZ) and cis-diamminedichloroplatinum (CDDP) in a time- and dose-dependent manner. Temozolomide 146-149 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 92-96 25035396-1 2014 Isocitrate dehydrogenase 1 (IDH1) mutations occur in most lower grade glioma and not only drive gliomagenesis but are also associated with longer patient survival and improved response to temozolomide. Temozolomide 188-200 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-26 25035396-1 2014 Isocitrate dehydrogenase 1 (IDH1) mutations occur in most lower grade glioma and not only drive gliomagenesis but are also associated with longer patient survival and improved response to temozolomide. Temozolomide 188-200 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 28-32 25035396-8 2014 These results show that mutant IDH1 drives a unique set of transformative events that indirectly enhance HR and facilitate repair of temozolomide-induced DNA damage and temozolomide resistance. Temozolomide 133-145 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 31-35 25035396-8 2014 These results show that mutant IDH1 drives a unique set of transformative events that indirectly enhance HR and facilitate repair of temozolomide-induced DNA damage and temozolomide resistance. Temozolomide 169-181 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 31-35 25035396-9 2014 The results also suggest that inhibitors of HR may be a viable means to enhance temozolomide response in IDH1-mutant glioma. Temozolomide 80-92 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 105-109 24748470-0 2014 IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Temozolomide 112-124 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 24748470-7 2014 Our study confirms the favorable prognostic value of IDH1 mutation and MGMT methylation in patients with AA treated with RT plus concomitant and adjuvant TMZ. Temozolomide 154-157 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 53-57 22291938-7 2012 However, in our further multivariable regression analysis, the independent prognostic effect of IDH1 mutation is limited when considering age, preoperative KPS score, extent of resection, TMZ chemotherapy, and Ki-67 protein expression levels, which might narrow its prognostic power in Chinese population in the future. Temozolomide 188-191 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 96-100 22752663-0 2013 IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. Temozolomide 147-159 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 24305712-3 2014 We hypothesized that radiographic treatment response would be significantly different between IDH1 mutant versus wild-type GBMs after radiotherapy (RT) and concurrent temozolomide (TMZ). Temozolomide 167-179 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 94-98 24305712-3 2014 We hypothesized that radiographic treatment response would be significantly different between IDH1 mutant versus wild-type GBMs after radiotherapy (RT) and concurrent temozolomide (TMZ). Temozolomide 181-184 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 94-98 24162810-9 2014 The study indicates that RT with concomitant and adjuvant TMZ is a relatively safe treatment associated with longer survival in patients with 1p/19q codeleted and IDH1 mutated tumors. Temozolomide 58-61 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 163-167 20975057-0 2010 IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Temozolomide 63-75 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 19933982-3 2009 METHODS: We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy. Temozolomide 122-134 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 60-64